Assenagon Asset Management S.A. Makes New $26.31 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG)

Assenagon Asset Management S.A. acquired a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,832,007 shares of the company's stock, valued at approximately $26,308,000. Assenagon Asset Management S.A. owned 1.51% of 10x Genomics at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Green Alpha Advisors LLC bought a new stake in 10x Genomics in the fourth quarter worth $355,000. Diversified Trust Co purchased a new position in shares of 10x Genomics during the 4th quarter worth about $511,000. JPMorgan Chase & Co. grew its holdings in 10x Genomics by 355.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company's stock valued at $8,027,000 after purchasing an additional 277,355 shares during the last quarter. Geode Capital Management LLC grew its holdings in 10x Genomics by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company's stock valued at $41,009,000 after purchasing an additional 42,777 shares during the last quarter. Finally, M&T Bank Corp bought a new stake in 10x Genomics in the third quarter worth about $203,000. 84.68% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

TXG has been the topic of a number of analyst reports. JPMorgan Chase & Co. cut their target price on 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research note on Wednesday, October 30th. Barclays reduced their target price on 10x Genomics from $21.00 to $19.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Citigroup lowered their target price on shares of 10x Genomics from $35.00 to $23.00 and set a "buy" rating for the company in a research note on Wednesday, October 30th. UBS Group cut their price target on shares of 10x Genomics from $25.00 to $20.00 and set a "neutral" rating on the stock in a report on Wednesday, October 30th. Finally, The Goldman Sachs Group decreased their price objective on shares of 10x Genomics from $16.00 to $14.00 and set a "sell" rating for the company in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $23.86.

10x Genomics Price Performance

NASDAQ TXG traded down $0.01 during midday trading on Friday, hitting $15.08. 1,324,480 shares of the company traded hands, compared to its average volume of 1,985,907. The company has a market cap of $1.83 billion, a PE ratio of -9.86 and a beta of 1.83. The company's 50-day simple moving average is $14.97 and its 200-day simple moving average is $17.98. 10x Genomics, Inc. has a 52 week low of $12.95 and a 52 week high of $51.22.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.04. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The firm had revenue of $151.65 million during the quarter, compared to analyst estimates of $158.84 million. During the same quarter in the previous year, the business posted ($0.51) EPS. 10x Genomics's revenue was down 1.3% on a year-over-year basis. On average, research analysts predict that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.